Galenica AG (LON:0ROG)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 3.86B +2.0% |
| Revenue (ttm) | 3.88B +5.5% |
| Net Income | 169.69M -1.0% |
| EPS | 3.40 -1.1% |
| Shares Out | n/a |
| PE Ratio | 22.75 |
| Forward PE | 20.61 |
| Dividend | 2.36 (2.86%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | 15,376 |
| Average Volume | 34,979 |
| Open | 83.00 |
| Previous Close | 82.46 |
| Day's Range | 81.30 - 83.00 |
| 52-Week Range | 81.30 - 103.00 |
| Beta | 0.29 |
| RSI | 27.77 |
| Earnings Date | Aug 6, 2026 |
About Galenica AG
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and prod... [Read more]
Financial Performance
In 2025, Galenica AG's revenue was 4.15 billion, an increase of 5.48% compared to the previous year's 3.93 billion. Earnings were 181.10 million, a decrease of -1.01%.
Financial numbers in CHF Financial StatementsNews
Galenica AG Earnings Call Transcript: H2 2025
Group sales grew 5.5% in 2025, with EBIT up 11.3% and strong cash flow supporting a 20% dividend increase. Strategic acquisitions, digital expansion, and efficiency gains drive positive 2026 guidance, despite ongoing price pressure and ERP transition delays.
Galenica AG Transcript: Investor Day 2025
Transformation is driven by culture, digitalization, and staff engagement, with major investments in logistics, diagnostics, and omni-channel pharmacy services. Growth is targeted through innovation, acquisitions, and efficiency, while regulatory changes and market trends are actively managed.
Galenica AG Earnings Call Transcript: H1 2025
Sales grew 5% in H1 2025, with improved profitability and cash flow. Guidance for 2025 is confirmed, with EBIT growth outlook raised to 7%-9% due to one-off effects. The acquisition of Labora Team expands into diagnostics, while market and regulatory pressures remain.
Galenica AG Earnings Call Transcript: H1 2024
Solid H1 2024 growth outpaced the market despite weather and IT challenges, with strong performance in products, brands, and local pharmacies. Guidance for 2024 is confirmed, expecting stronger H2 growth, while ERP rollout and high generic substitution rates remain key headwinds.